Experience RGW

Clinical Research Trial to Study Safety and Efficacy
Of Micro-injector to Deliver Medication to Retinal
Vein Occlusion Patients Now Open for Enrollment

Posted in Announcements

The TOPAZ research trial—sponsored by Clearside Biomedical, Inc—is a randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal (SC) CLS-TA administered adjunctively with Intravitreal Aflibercept (Eylea®) in subjects with newly diagnosed Retinal Vein Occlusions. The primary objective is to demonstrate this method of treatment in patients with macular edema secondary to retinal vein occlusion as superior to IVT alone using Best Corrected Visual Acuity outcome. This Phase 3, multicenter, randomized, masked, controlled parallel group will be treated with suprachoroidal injections in a novelty drug micro-injector delivery to precisely administer the medication to more rapidly resolve Macular Edema and improve vision, as compared to the current traditional monotherapy for Retinal Vein Occlusion. This study is projected to enroll 460 eligible subjects who have been newly diagnosed (<9 months) and are naïve to prior treatment, randomly assigned 1:1 of stratified Branch Retinal Vein Occlusion and Central Retinal Vein Occlusion groups. 

Enrollment is now open for this 50-week study—including 12 clinic visits—in our Chevy Chase office. Trials will be conducted under the direction of Clinical Research Coordinators Maya Talatory, Maggie Cashion and Irene Fanous. Their contact information is as follows:

Maya: (301-986-1477/mtalatory@rgw.com)
Maggie: (301-951-4319/mcashion@rgw.com)
Irene: (703-564-7519/ifanous@rgw.com)

Return to Announcements